Glioblastoma Multiforme（GBM）是一种侵袭性脑癌，影响胶质细胞，具有化疗和放疗耐受性。葡萄糖被认为是癌细胞增殖的最重要能量来源。在代谢过程中，六碳糖分子将通过被称为葡萄糖转运蛋白（GLUT）的跨膜蛋白质被运输到细胞内。其中，GLUT-1和GLUT-3在GBM中的葡萄糖转运中起着至关重要的作用。敲除研究已经证实了GLUT-1和GLUT-3介导的GBM细胞的葡萄糖转运作用，为了解GLUT介导的癌症信号和癌症侵袭提供了见解。本文重点介绍了GLUT-1和GLUT-3蛋白在调节葡萄糖转运方面的重要作用。最近的研究已经确认了GLUT抑制剂在有效防癌方面的作用。其中一些正在进行临床试验。了解和实现葡萄糖介导的细胞代谢和染色质表观遗传学方法将为进一步了解GBM中的癌症侵袭机制、癌症干性和化疗耐受性提供宝贵的见解。本综述总结了GLUT抑制剂、微小RNA和长链非编码RNA的作用，这些RNA有助于抑制GBM细胞和其他癌症细胞的葡萄糖摄取，导致潜在治疗、预后和诊断标记的识别。此外，还证明了表观遗传学因素，例如微小RNA，在调节糖解基因方面的作用。©2023作者，独家许可Springer Science+Business Media，LLC和Springer Nature的一部分。

Glioblastoma Multiforme (GBM) is an aggressive brain cancer affecting glial cells and is chemo- and radio-resistant. Glucose is considered the most vital energy source for cancer cell proliferation. During metabolism, hexose molecules will be transported into the cells via transmembrane proteins known as glucose transporter (GLUT). Among them, GLUT-1 and GLUT-3 play pivotal roles in glucose transport in GBM. Knockdown studies have established the role of GLUT-1, and GLUT-3 mediated glucose transport in GBM cells, providing insight into GLUT-mediated cancer signaling and cancer aggressiveness. This review focussed on the vital role of GLUT-1 and GLUT-3 proteins, which regulate glucose transport. Recent studies have identified the role of GLUT inhibitors in effective cancer prevention. Several of them are in clinical trials. Understanding and functional approaches towards glucose-mediated cell metabolism and chromatin epigenetics will provide valuable insights into the mechanism of cancer aggressiveness, cancer stemness, and chemo-resistance in Glioblastoma Multiforme (GBM). This review summarizes the role of GLUT inhibitors, micro-RNAs, and long non-coding RNAs that aid in inhibiting glucose uptake by the GBM cells and other cancer cells leading to the identification of potential therapeutic, prognostic as well as diagnostic markers. Furthermore, the involvement of epigenetic factors, such as microRNAs, in regulating glycolytic genes was demonstrated.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.